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INVITED COMMENTARY
Ronald Dalman, MD, Stanford, Calif
Despite progressive improvement in endovascular device de-
sign and deployment techniques, a small but significant fraction of
post-endovascular aneurysm repair (EVAR) patients continue to
experience late aneurysm-related complications. In light of the
recent US Food and Drug Administration Public Health Notice
regarding increasing late aneurysm-relatedmortality following EVAR
(http://www.fda.gov/cdrh/safety/031808-medtronic.html), this
prospective, randomized trial of adjuvant doxycycline therapy to
improve procedural durability seems particularly timely. While
providing tantalizing insights into potential mechanisms of inter-
est, this study does not clarify the potential value of doxycycline as
either adjuvant or primary therapy for abdominal aortic aneurysm
(AAA) disease.
Primary study endpoints included (1) a reduction in plasma
matrix metalloproteinases (MMP)-9 levels with doxycycline
therapy and (2) a reduction in aneurysm sac size at 6 months.
Secondary endpoints included plasma MMP-2, serum IL-6,
IL-8, and highly-sensitive C-reactive protein (hs-CRP) levels
at 6 months. Of these, only plasma MMP-9 levels were noted
to decrease in doxycycline-treated patients between 1 and 6
months following EVAR. Doxycycline-induced reductions in
plasma MMP-9 levels did not translate into reduced AAA sac
size. While endograft-specific outcome analyses suggested evi-
dence of enhanced aneurysm sac and neck stability with doxy-
cycline, these were post-hoc analyses to be interpreted with
caution. These types of analyses are best used to generate
additional hypotheses for further study.
Prior studies (including reference 16 of the article above) have
suggested that post-procedural plasma MMP levels are reduced
following either open surgical repair or EVAR, particularly in the
absence of endoleaks. In placebo treated patients in the current
series, interestingly, plasma MMP-9 levels actually rose slightly
following endografting. Why these plasma responses to EVAR
should differ between these series is unclear. This also highlights
the uncertain clinical relevance of reduced plasmaMMP-9 levels in
the absence of significant structural effects: in reference 5, plasma
MMP-9 levels were reduced following oral doxycycline therapy in
small AAA patients even though no influence was noted on ultra-
sound-determined diameter enlargement. Clearly more conclusive
data is needed, requiring much larger treatment groups appropri-
ately stratified by size, endoleak status, device type and exclusion
methodology (eg, uni-iliac vs bifurcated device, etc), thrombus
size and location and all other variables known or suspected to
influence late aneurysm remodeling and regression following
EVAR.
Most importantly this intriguing study underscores the
need for rigorous and fully-powered trials to test the ability of
doxycycline to suppress mural proteolysis in AAA, either follow-
ing EVAR or as primary therapy to limit progression of early
disease. More than 10 years after the original studies suggesting
potential efficacy, fully-funded clinical trials are long overdue
and clearly justified. Patients deserve to know whether or not
doxycycline therapy will reduce their risks of death and disability
from AAA disease.
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